Left Ventricular Mass Index as a Predictor of New-Onset Microalbuminuria in Hypertensive Subjects: A Prospective Study

被引:11
作者
Andrikou, Eirini [1 ]
Tsioufis, Costas [1 ]
Thomopoulos, Costas [1 ]
Andrikou, Ioannis [1 ]
Kasiakogias, Alexandros [1 ]
Leontsinis, Ioannis [1 ]
Kordalis, Athanasios [1 ]
Katsimichas, Themis [1 ]
Tousoulis, Dimitrios [1 ]
Stefanadis, Christodoulos [1 ]
机构
[1] Univ Athens, Hippokration Hosp, Cardiol Clin 1, Athens, Greece
关键词
blood pressure; blood pressure control; hypertension; left ventricular mass; microalbuminuria; END-POINT REDUCTION; CARDIOVASCULAR MORBIDITY; LOSARTAN INTERVENTION; RISK; HYPERTROPHY; DISEASE; ALBUMINURIA; REGRESSION; MORTALITY; OUTCOMES;
D O I
10.1038/ajh.2012.109
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND We aimed to investigate the predictive role of left ventricular mass and its reduction on the development of new-onset microalbuminuria (MA) in newly diagnosed hypertensive patients. METHODS A total of 207 nondiabetic, normoalbuminuric patients without clinical organ damage (aged 50.8 +/- 10.1 years, 132 male, 84 smokers) with baseline office blood pressure (BP) 148/96 mm Hg were followed for a mean period of 3.3 +/- 1.3 years. At baseline and last follow-up visit, all patients underwent office and 24-h ambulatory BP monitoring, albumin to creatinine ratio (ACR) determination, and echocardiographic assessment of left ventricular mass index (LVMI). All patients were treated with antihypertensive therapy during the follow-up period. We defined MA as ACR between 20 and 300 mg/g for men and 30-300 mg/g for women, effective BP control as office BP <140/90 mm Hg in >= 75% of total number of visits, and LVMI reduction as the decline of LVMI at end-follow-up of >= 15% with respect to the baseline value. RESULTS Between baseline and last follow-up visit, LVMI decreased by 6.84 +/- 21.5 g/m(2) (P < 0.01); 64.3% (n = 133) of participants achieved BP control during the follow-up period. Of the total population, 5.8% (n = 12) developed MA during follow-up. Cox-regression analysis, after adjustment for clinical variables, revealed that increase of LVMI by 1 s.d. (23.3 g/m(2)) conferred a 15% increased risk of new-onset MA, while LVMI reduction and BP control were both associated with almost 100% reduced risk of MA development. CONCLUSIONS LVMI and its reduction were qualified as predictors of new-onset MA in newly diagnosed hypertensive patients, beyond BP control.
引用
收藏
页码:1195 / 1201
页数:7
相关论文
共 31 条
[1]   Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria [J].
Anavekar, NS ;
Gans, DJ ;
Berl, T ;
Rohde, RD ;
Cooper, W ;
Bhaumik, A ;
Hunsicker, LG ;
Rouleau, JL ;
Lewis, JB ;
Rosendorff, C ;
Porush, JG ;
Drury, PL ;
Esmatjes, E ;
Raz, I ;
Vanhille, P ;
Locatelli, F ;
Goldhaber, S ;
Lewis, EJ ;
Pfeffer, MA .
KIDNEY INTERNATIONAL, 2004, 66 :S50-S55
[2]   Parallel Deterioration of Albuminuria, Arterial Stiffness and Left Ventricular Mass in Essential Hypertension: Integrating Target Organ Damage [J].
Andrikou, Eirini ;
Tsioufis, Costas ;
Dimitriadis, Kyriakos ;
Flessas, Dimitrios ;
Chatzistamatiou, Vagelis ;
Grassos, Charalampos ;
Papavasiliou, Maria ;
Papadopoulos, Dimitris ;
Stefanadis, Christodoulos .
NEPHRON CLINICAL PRACTICE, 2011, 119 (01) :C27-C34
[3]   Essential Hypertension Is There a Role for Inflammatory Mechanisms? [J].
Androulakis, Emmanuel S. ;
Tousoulis, Dimitris ;
Papageorgiou, Nikolaos ;
Tsioufis, Costas ;
Kallikazaros, Ioannis ;
Stefanadis, Christodoulos .
CARDIOLOGY IN REVIEW, 2009, 17 (05) :216-221
[4]  
[Anonymous], 2004, Am J Kidney Dis, V43, pS1, DOI DOI 10.1053/J.AJKD.2004.03.003
[5]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[6]   Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J].
Devereux, RB ;
Dahlöf, B ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, KE ;
Edelman, JM ;
Wachtell, K .
CIRCULATION, 2004, 110 (11) :1456-1462
[7]   Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients -: Losartan intervention for endpoint reduction in hypertension study [J].
Ibsen, H ;
Olsen, MH ;
Wachtell, K ;
Borch-Johnsen, K ;
Lindholm, LH ;
Mogensen, CE ;
Dahlöf, B ;
Devereux, RB ;
de Faire, U ;
Fyhrquist, F ;
Julius, S ;
Kjeldsen, SE ;
Lederballe-Pedersen, O ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wan, Y .
HYPERTENSION, 2005, 45 (02) :198-202
[8]   Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects -: Five-year follow-up of the Hoorn study [J].
Jager, A ;
Kostense, PJ ;
Ruhé, HG ;
Heine, RJ ;
Nijpels, G ;
Dekker, JM ;
Bouter, LM ;
Stehouwer, CDA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :617-624
[9]   Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals [J].
Jensen, JS ;
FeldtRasmussen, B ;
BorchJohnsen, K ;
Clausen, P ;
Appleyard, M ;
Jensen, G .
JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (11) :727-732
[10]   Do we understand why regression of left ventricular hypertrophy is beneficial? [J].
Kaplinsky, E .
CARDIOVASCULAR RESEARCH, 2003, 60 (03) :463-464